Patents by Inventor Robert A. Kastelein

Robert A. Kastelein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mammalian receptor proteins DCRS5; method of treatment
    Patent number: 7887806
    Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: February 15, 2011
    Assignee: Schering Corporation
    Inventors: Madaline Chirica, Robert A. Kastelein, Kevin Moore, Christi L. Parham
  • IL-12P40 and IL-B30 polypeptide complex
    Patent number: 7883695
    Abstract: Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: August 10, 2006
    Date of Patent: February 8, 2011
    Assignee: Schering Corporation
    Inventors: Birgit Oppmann, Rene de Waal Malefyt, Donna M. Rennick, Robert A. Kastelein, Maria T. Wiekowski, Sergio A. Lira, Satwant K. Narula
  • Uses of Mammalian Cytokine; Related Reagents
    Publication number: 20110002928
    Abstract: Provided are methods of treatment for inflammatory and autoimmune disorders of the metabolic system. Also provided are methods of diagnosis.
    Type: Application
    Filed: September 17, 2010
    Publication date: January 6, 2011
    Applicant: Schering Corporation
    Inventors: Daniel J. Cua, Robert A. Kastelein
  • USE OF IL-23 ANTAGONISTS FOR TREATMENT OF INFECTION
    Publication number: 20100291084
    Abstract: Methods and compositions comprising antagonists of IL-23 are provided for the treatment of infections, such as chronic bacterial, viral and fungal infections.
    Type: Application
    Filed: February 8, 2008
    Publication date: November 18, 2010
    Inventors: Manfred Kopf, Luigina Romani, Robert A. Kastelein, Alissa A. Chackerian
  • Mammalian Receptor Proteins; Related Reagents and Methods
    Publication number: 20100278825
    Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Application
    Filed: July 12, 2010
    Publication date: November 4, 2010
    Applicant: SCHERING CORPORATION
    Inventors: MADALINE CHIRICA, ROBERT A. KASTELEIN, KEVIN W. MOORE, CHRISTI L. PARHAM
  • Treatment of diabetes using antibodies to IL-23, IL-23 receptor and IL-17
    Patent number: 7820168
    Abstract: The instant specification provides methods of treatment for inflammatory and autoimmune disorders of the metabolic system. The instant specification also provides methods of diagnosis.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: October 26, 2010
    Assignee: Schering Corporation
    Inventors: Daniel J. Cua, Robert A. Kastelein
  • HUMAN RECEPTOR PROTEINS; RELATED REAGENTS AND METHODS
    Publication number: 20100266599
    Abstract: Nucleic acids encoding mammalian Toll-like receptors (TLRs) have been identified in human cells. Recombinantly produced TLRs are used in the preparation of antibodies that are capable of binding to the TLRs. The antibodies are advantageously used in the prevention and treatment of septic shock, inflammatory conditions, and viral infections.
    Type: Application
    Filed: March 2, 2010
    Publication date: October 21, 2010
    Inventors: GERARD T. HARDIMAN, FERNANDO L. ROCK, J. FERNANDO BAZAN, ROBERT A. KASTELEIN, STEPHEN W.K. HO, YONG-JUN LIU
  • Mammalian Receptor Proteins; Related Reagents and Methods
    Publication number: 20100261273
    Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Application
    Filed: June 17, 2010
    Publication date: October 14, 2010
    Applicant: Schering Corporation
    Inventors: Madaline Chirica, Robert A. Kastelein, Kevin W. Moore, Christi L. Parham
  • Use of Cytokine Expression to Predict Skin Inflammation; Methods of Treatment
    Publication number: 20100254991
    Abstract: Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and/or IL-23.
    Type: Application
    Filed: June 17, 2010
    Publication date: October 7, 2010
    Applicants: Schering Corporation, Schering Corporation, Schering Corporation, Schering Corporation
    Inventors: Robert A. Kastelein, Terrill K. McClanahan, Erin Murphy, Jason R. Chan
  • PURIFIED MAMMALIAN CYTOKINES; RELATED REAGENTS AND METHODS
    Publication number: 20100210012
    Abstract: CTLA-8 related antigens from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigens. Methods of using said reagents and diagnostic kits are also provided.
    Type: Application
    Filed: November 11, 2009
    Publication date: August 19, 2010
    Inventors: DANIEL M. GORMAN, J. Fernando Bazan, Robert A. Kastelein, Gerard Zurawski
  • Method of treating skin inflammation
    Patent number: 7776540
    Abstract: Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17 and/or IL-23.
    Type: Grant
    Filed: September 2, 2008
    Date of Patent: August 17, 2010
    Assignee: Schering Corporation
    Inventors: Robert A. Kastelein, Terrill K. McClanahan, Erin Murphy
  • Mammalian receptor protein DCRS5; methods of treatment
    Patent number: 7754214
    Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Grant
    Filed: July 28, 2008
    Date of Patent: July 13, 2010
    Assignee: Schering Corporation
    Inventors: Madaline Chirica, Robert A. Kastelein, Kevin W. Moore, Christi L. Parham
  • Method for raising or isolating an antibody to DCRS5
    Patent number: 7749718
    Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Grant
    Filed: July 28, 2008
    Date of Patent: July 6, 2010
    Assignee: Schering Corporation
    Inventors: Madaline Chirica, Robert A. Kastelein, Kevin W. Moore, Christi L. Parham
  • Method of treatment of skin inflammation
    Patent number: 7740848
    Abstract: Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and/or IL-23.
    Type: Grant
    Filed: September 2, 2008
    Date of Patent: June 22, 2010
    Assignee: Schering Corporation
    Inventors: Robert A. Kastelein, Terrill K. McClanahan, Erin Murphy, Jason R. Chan
  • Uses of Mammalian Cytokine; Related Reagents
    Publication number: 20100143357
    Abstract: Provided are methods of treatment for inflammatory and autoimmune disorders of the central nervous system and gastrointestinal tract. Also provided are methods of diagnosis.
    Type: Application
    Filed: February 19, 2010
    Publication date: June 10, 2010
    Applicant: SCHERING CORPORATION
    Inventors: Daniel J. Cua, Yi Chen, Robert A. Kastelein, Claire L. Langrish, Donna M. Rennick, Jonathon Sedgwick
  • COMBINATION THERAPY FOR TREATMENT OF IMMUNE DISORDERS
    Publication number: 20100135998
    Abstract: Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of Th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of IL-23 is continued for a longer time to prevent recurrence of the acute event. Antagonists of PGE2 and CD161 are also disclosed for use in treatment of autoimmune, inflammatory and proliferative disorders.
    Type: Application
    Filed: February 26, 2008
    Publication date: June 3, 2010
    Inventors: Edward Paul Bowman, Daniel J. Cua, Robert A. Kastelein, Kathy Lynn Miller, Melanie A. Kleinschek, Kristian S. Bak-Jensen, Katia Boniface, Brent S. McKenzie, Rene de Waal Malefyt
  • USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE
    Publication number: 20100111954
    Abstract: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
    Type: Application
    Filed: December 21, 2009
    Publication date: May 6, 2010
    Inventors: Daniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver, Dror Luger
  • USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE
    Publication number: 20100111950
    Abstract: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
    Type: Application
    Filed: December 21, 2009
    Publication date: May 6, 2010
    Inventors: Daniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver, Dror Luger
  • Human DNAX toll-like receptor 4 proteins, related reagents and methods
    Patent number: 7670603
    Abstract: Nucleic acids encoding mammalian Toll-like receptors (TLRs) have been identified in human cells. Recombinantly produced TLRs are used in the preparation of antibodies that are capable of binding to the TLRs. The antibodies are advantageously used in the prevention and treatment of septic shock, inflammatory conditions, and viral infections.
    Type: Grant
    Filed: April 9, 2008
    Date of Patent: March 2, 2010
    Assignee: Schering Corporation
    Inventors: Gerard T. Hardiman, Fernando L. Rock, J. Fernando Bazan, Robert A. Kastelein, Stephen W. K. Ho, Yong-Jun Liu
  • IL-17-like cytokine binding compounds and antibodies
    Patent number: 7655761
    Abstract: CTLA-8 related antigens from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigens. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: December 7, 2007
    Date of Patent: February 2, 2010
    Assignee: Schering Corporation
    Inventors: Daniel M. Gorman, J. Fernando Bazan, Robert A. Kastelein, Gerard Zurawski